NFKB1 and metabolic dysfunction-associated steatohepatitis: Indeed, more than 700 NF-κB inhibitors that target various stages of the NF-κB signaling pathway have been developed [11], and some of them have commenced clinical trials for inflammatory liver diseases, including autoimmune hepatitis, non-alcoholic steatohepatitis, and chronic hepatitis C viral infection [12].